Trial Profile
A Randomized, Open-label, Multicentric Phase II Trial of PEMBROLIZUMAB (Keytruda®) With Chemotherapy Versus Chemotherapy Alone (Standard of Care) as Neo Adjuvant Treatment of Ovarian Cancer Not Amenable to Front Line Debulking Surgery.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms NEOPEMBROV
- Sponsors ARCAGY/GINECO Group
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 21 Jan 2021 Time frame of the primary end-point is changed from 5 years to 4 months.
- 21 Jan 2021 Planned End Date changed from 1 Sep 2022 to 31 Mar 2025.